Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

FLT3 internal tandem duplication is a poor risk factor in patients with AML with diverse cytogenetic features (CROSBI ID 580913)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa

Mikulic, Mirta ; Zadro, Renata ; Davidovic, Sanja ; Serventi Seiwerth, Ranka ; Sertic, Dubravka ; Nemet, Damir ; Batinic, Josip ; Batinic, Drago ; Gjadrov, Koraljka ; Ries, Sunčica et al. FLT3 internal tandem duplication is a poor risk factor in patients with AML with diverse cytogenetic features // Liječnički vjesnik : glasilo Hrvatskog liječničkog zbora. Suplement / Arić, Branimir (ur.). 2011. str. 90-90

Podaci o odgovornosti

Mikulic, Mirta ; Zadro, Renata ; Davidovic, Sanja ; Serventi Seiwerth, Ranka ; Sertic, Dubravka ; Nemet, Damir ; Batinic, Josip ; Batinic, Drago ; Gjadrov, Koraljka ; Ries, Sunčica ; Labar, Boris

engleski

FLT3 internal tandem duplication is a poor risk factor in patients with AML with diverse cytogenetic features

Aim: Mutations of Fms-like tyrosine kinase 3 (FLT3) are present in about 30% of acute myelogenous leukemia (AML) patients that have been shown to have poor prognosis. The aim of this study was to analyze the prognostic impact of FLT3 internal tandem duplication (ITD) on the outcome of patients diagnosed with AML in comparison with patients with wild-type (WT) FLT3. Patients and methods: We retrospectively analyzed the laboratory and clinical data in 78 newly diagnosed patients with AML who have been treated in our Center from 02/2000-03/2010. Median patients’ age was 45 years (range, 22–72 yrs.). AML diagnosis was based on morphological, immunophenotypical and cytogenetical features. The presence of FLT3 ITD was detected by RT-PCR analysis. All patients received intensive induction chemotherapy followed by consolidation chemotherapy ; 36 patients were treated with autologous hematopoietic stem cell transplantation (SCT) in 1st CR, while 8 and 3 patients were allografted in 1st and >1st CR, respectively. Results: FLT3-ITD was detected in 20 patients (25%). Eight FLT3-ITD patients had normal karyotypes, two had good, and two had intermediate cytogenetic features. Thirteen FLT3-WT patients had normal karyotypes, five had good, nine had poor, and nine had intermediate cytogenetic features. In 30 patients from both groups cytogenetic studies had failed. CR rate was 85% in FLT3-ITD patients and 71% in FLT3-WT patients (p=0.249). 2-year DFS was 33.8 and 52.5% in the FLT3-ITD and FLT3-WT group, respectively (p=0.029). 2- year OS was 47.3 and 63% in the FLT3- ITD and FLT3-WT group, respectively (p=0.665). Conclusion: A higher remission rate after induction, although not statistically significant, was found in the FLT3- ITD group. Contrary to that, the DFS was significantly better in patients with FLT3-WT and a trend for better OS was observed in patients with FLT3- WT. This data support the evidence for FLT3-ITD being a poor risk factor, not only in patients with normal karyotypes, but also in patients with different cytogenetic risk factors.

FLT3 ; risk factors ; AML

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

90-90.

2011.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Liječnički vjesnik : glasilo Hrvatskog liječničkog zbora. Suplement

Arić, Branimir

Zagreb: Hrvatski liječnički zbor

1330-4917

Podaci o skupu

2nd Leukemia and Lymphoma Meeting – East and West Are Together

poster

17.09.2011-21.09.2011

Dubrovnik, Hrvatska

Povezanost rada

Kliničke medicinske znanosti